Maubec et al. evaluated the outcome of first-line pembrolizumab in patients with unresectable cSCC and reported an ORR of 41% and median OS of 25 months, with patients having PD-L1+ status having a higher response (55%) compared to patients with negative PD-L1 status. This evidence concerns the gene CD274 and skin squamous cell carcinoma.